Loading...
In patients with diabetes mellitus (DM), microalbuminuria predicts early development of nephropathy and cardiovascular (CV) disease; treatment with angiotensin-converting–enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is recommended for patients with established microalbuminuria. In this trial, investigators assessed the value of the ARB olmesartan (Benicar) for preventing development of microalbuminuria. The drug's maker funded the study, and most of the authors had financial relationships with the company.
About 4400 patients (mean age, 58) with type 2 DM, normoalbuminuria, and mean blood pressure of 136/81 mm Hg were randomized to daily olmesartan (40 mg) or placebo, with unrestricted use of antihypertensives other than A…